| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RPL34 |
| Uniprot No | P49207 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-117aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMVQRLTYRRRLSYNTASNKTRLSRTPG NRIVYLYTKKVGKAPKSACGVCPGRLRGVRAVRPKVLMRLSKTKKHVSRA YGGSMCAKCVRDRIKRAFLIEEQKIVVKVLKAQAQSQKAK |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RPL34重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*RPL34 promotes cell proliferation and invasion in hepatocellular carcinoma through PI3K/AKT signaling pathway*
**作者**：Li Y, et al.
**摘要**：该研究发现RPL34在肝癌组织中高表达，通过重组蛋白实验证实其通过激活PI3K/AKT通路促进肿瘤细胞增殖和侵袭，提示其作为肝癌潜在治疗靶点。
2. **文献名称**：*Recombinant RPL34 suppresses apoptosis via stabilizing Bcl-2 in colorectal cancer cells*
**作者**：Wang X, et al.
**摘要**：研究利用重组RPL34蛋白验证其在结直肠癌细胞中的抗凋亡功能，发现其通过稳定Bcl-2蛋白抑制线粒体凋亡途径，促进癌细胞存活。
3. **文献名称**：*Expression and purification of human RPL34 recombinant protein for structural analysis*
**作者**：Zhang L, et al.
**摘要**：本文报道了利用大肠杆菌表达系统高效表达和纯化人源RPL34重组蛋白的方法，并初步解析其结构特征，为后续功能研究提供基础工具。
4. **文献名称**：*RPL34 modulates cell cycle progression by interacting with CDK4 in breast cancer*
**作者**：Chen H, et al.
**摘要**：通过重组蛋白互作实验，揭示了RPL34与CDK4直接结合并加速细胞周期G1/S期转换，促进乳腺癌发展的分子机制。
(注：以上文献信息为示例性内容，实际引用需以真实发表文献为准。)
The RPL34 recombinant protein is derived from the ribosomal protein L34. a crucial component of the 60S ribosomal subunit in eukaryotes. As part of the ribosome, RPL34 plays a fundamental role in protein synthesis by facilitating mRNA decoding and peptide bond formation. The gene encoding RPL34 is evolutionarily conserved across species, underscoring its essential biological function. Structurally, it contains conserved domains that mediate interactions with rRNA and other ribosomal proteins to maintain ribosome integrity.
Recombinant RPL34 is typically produced using prokaryotic expression systems (e.g., E. coli) or eukaryotic systems (e.g., yeast or mammalian cells) for research applications. The protein is engineered with tags (e.g., His-tag) for simplified purification and detection. Post-translational modifications, if required, can be achieved through eukaryotic expression platforms.
Interest in RPL34 extends beyond basic ribosome biology. Studies link its dysregulation to various pathologies. Overexpression has been observed in multiple cancers (e.g., hepatocellular carcinoma, leukemia), where it potentially promotes cell proliferation by modulating ribosome biogenesis and translation efficiency. Conversely, mutations in RPL34 are associated with ribosomopathies—rare disorders characterized by bone marrow failure or developmental abnormalities. Emerging evidence also suggests non-ribosomal functions, including interactions with tumor suppressors like p53 to influence cell cycle regulation.
Researchers employ recombinant RPL34 to investigate ribosome assembly mechanisms, explore cancer biomarkers, and model ribosomopathies in cellular or animal systems. Its application extends to drug discovery, particularly in screening compounds targeting ribosome-related oncogenic pathways. However, functional studies require careful interpretation due to potential pleiotropic effects from ribosomal/non-ribosomal roles.
This recombinant tool continues to advance our understanding of ribosome biology and its implications in disease, bridging structural insights with therapeutic opportunities.
×
